With Hong Kong, We Go Further
Outlook and Vision
The Government will continue to enhance Hong Kong's clinical trial capability on all fronts and facilitate the translation of innovative biomedical research results into clinical applications.
Extend the R&D network and expedite clinical trials.
Accelerate approval for registration of new drugs in Hong Kong, the Mainland and overseas.
Attract top-notch innovative enterprises to set up operations in Hong Kong.
Strategic Location
-
Hong Kong
One Country and Two Systems, Strong Support of the Motherland, Closely Connected to the World.
-
Hetao area
One Zone, Two Parks, Technological Innovation, Institutional Innovation, Cross-boundary Facilitation.
-
Guangdong-Hong Kong-Macao Greater Bay Area (GBA)
Population Over 86 Million, Special Measures of Using HK Registered Drugs and Medical Devices Used in HK Public Hospitals in GBA.
Facilities
Temporary Office and Biobank Facility
Equipped with several executive offices, meeting rooms, and a multipurpose space.
Biobank Facility managed by the Hospital Authority in collaboration with The Chinese University of Hong Kong.
Sample collection, deposition and access comply with internationally recognised ethical standards.
Properly store data in independent laboratory information management system.